ZyVersa Therapeutics, Inc.
Navigate ZyVersa Therapeutics, Inc.
Home
About
About
Our Vision/Mission
Management Team
Board of Directors
Scientific Advisory Board: Inflammatory Diseases
Scientific Advisory Board: Renal Disease
Inflammasomes
Inflammasomes
IC 100: ASC Inhibitor
ASC Biomarker
Inflammasome Publications
IC 100 Infographic, Mechanism of Action
White Paper: Inflammasomes, a Promising Therapeutic and Diagnostic Target
Renal Lipids
Renal Lipids
VAR 200, Cholesterol Efflux Mediator, 2HPβCD
Cyclodextrin Publications
Pipeline
Pipeline
Collaboration
About FSGS
About Alport Syndrome
About Lupus nephritis
About Diabetic Kidney Disease
About Multiple Sclerosis
About NASH
Careers
News Center
Corporate News Releases
Corporate Presentations
Media Resources
Corporate Media Contact
Contact
Announcement
Variant Pharmaceuticals Has a New Name - ZyVersa Therapeutics, Inc.
Home
News Center
Corporate News Releases
Corporate News Releases
May 28, 2019 • 7:08 AM EDT
ZyVersa Therapeutics to Attend the World's Largest Biotechnology Partnering Event, BIO International (Philadelphia, June 3 - 6, 2019)
May 23, 2019 • 7:08 AM EDT
ZyVersa Therapeutics Announces Appointment of International Investor, Andrew (DW) Kim, to its Board of Directors
May 21, 2019 • 7:08 AM EDT
Experts on the Forefront of Inflammasome Research Will Serve on ZyVersa Therapeutics' Inaugural Immunology Scientific Advisory Board
May 15, 2019 • 7:08 AM EDT
ZyVersa Therapeutics Enhances Scientific Advisory Board with Three Esteemed Nephrologists
May 7, 2019 • 7:08 AM EDT
Jules A. Müsing, Former Senior Executive at Johnson & Johnson, Has Been Appointed Chairman of ZyVersa Therapeutics' Board of Directors
May 1, 2019 • 7:03 AM EDT
Variant Pharmaceuticals Has a New Name - ZyVersa Therapeutics, Inc.
Apr 22, 2019 • 7:08 AM EDT
Variant Pharmaceuticals Expands Development Focus Into $60+ Billion Anti-inflammatory Market with Worldwide License to Novel Inflammasome Inhibitor
Dec 3, 2018 • 7:08 AM EST
Variant Pharmaceuticals Secures $10 Million in Financing from Korean Company, Incon Co., Ltd.
Oct 30, 2018 • 7:08 AM EDT
Variant Pharmaceuticals Submits Application for U.S. Orphan Drug Designation for VAR 200 (2-Hydroxypropyl-β-Cyclodextrin) To Treat Focal Segmental Glomerulosclerosis (FSGS)
Oct 24, 2018 • 1:08 PM EDT
Variant Pharmaceuticals Announces Publication of Data Demonstrating 2-Hydroxypropyl-β-Cyclodextrin (2HPβCD) Protects Against Kidney Disease in Experimental Models of Alport Syndrome (AS) and Focal Segmental Glomerulosclerosis (FSGS)